View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 30, 2020

University of Oxford starts enrolment for Covid-19 vaccine trial

Researchers at the University of Oxford in the UK have commenced enrolment of healthy volunteers for a clinical trial of the Covid-19 vaccine candidate ChAdOx1 nCoV-19.

Researchers at the University of Oxford in the UK have commenced enrolment of healthy volunteers for a clinical trial of the Covid-19 vaccine candidate ChAdOx1 nCoV-19.

The vaccine is based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein. It is currently in production at the university’s Clinical Biomanufacturing Facility and is expected to be ready in the coming weeks.

The trial is designed to enrol up to 510 participants aged 18 to 55 and is being conducted by the university’s Jenner Institute and Oxford Vaccine Group.

The study will assess the vaccine candidate’s safety and ability to induce an immune response against the novel coronavirus. ChAdOx1 nCoV-19 will be compared to a control injection.

The University of Oxford noted that the vaccine will undergo additional preclinical tests and will be manufactured in large quantities before entering the trial.

Jenner Institute director Adrian Hill said: “The Oxford team had exceptional experience of a rapid vaccine response, such as to the Ebola outbreak in West Africa in 2014. This is an even greater challenge.

“Vaccines are being designed from scratch and progressed at an unprecedented rate. The upcoming trial will be critical for assessing the feasibility of vaccination against Covid-19 and could lead to early deployment.”

Researchers are scaling up the vaccine’s production for larger trials and potential future development.

Vaccine manufacturing scale-up project lead Dr Sandy Douglas said: “The scale of this epidemic poses a huge challenge for vaccine manufacturing. We need to follow rigorous safety standards and that takes time.

“By starting work on large-scale manufacturing immediately, we hope to accelerate the availability of a high quality, safe vaccine.”

Last week, a research team at the university initiated the RECOVERY clinical trial to assess different drugs as potential Covid-19 treatments.

To be conducted in hospitalised adult patients, RECOVERY will initially evaluate HIV drugs lopinavir and ritonavir and anti-inflammation medication dexamethasone.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU